Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment

References

• Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329–11. doi:10.1146/annurev.immunol.22.012703.104803. Epub 2004/03/23. PubMed PMID: 15032581.
   PubMed Web of Science ®Google Scholar
• Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer. 2018; 18(3):139–147. doi:10.1038/nrc.2017.117. Epub 2018/01/13. PubMed PMID: 29326431.
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017; 17(9):559–572. doi:10.1038/nri.2017.49. Epub 2017/05/31. PubMed PMID: 28555670; PubMed Central PMCID: PMCPMC5731833.
   PubMed Web of Science ®Google Scholar
• Lu B, Yang M, Wang Q. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy. J Mol Med (Berl). 2016; 94(5):535–543. doi:10.1007/s00109-016-1397-0. Epub 2016/ 02/29. PubMed PMID: 26922618.
   PubMed Web of Science ®Google Scholar
• Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013; 138(2):105–115. doi:10.1111/imm.12036. Epub 2012/ 12/12. PubMed PMID: 23216602; PubMed Central PMCID: PMCPMC3575763.
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267–296. doi:10.1146/annurev.immunol.25.022106.141609. Epub 2006/ 12/01. PubMed PMID: 17134371; PubMed Central PMCID: PMCPMC2895922.
   PubMed Web of Science ®Google Scholar
• Frankel T, Lanfranca MP, Zou W. The Role of Tumor Microenvironment in Cancer Immunotherapy. Adv Exp Med Biol. 2017;1036:51–64. doi:10.1007/978-3-319-67577-0_4. Epub 2017/ 12/25. PubMed PMID: 29275464.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015; 15(8):486–499. doi:10.1038/nri3862. Epub 2015/ 07/25. PubMed PMID: 26205583; PubMed Central PMCID: PMCPMC4889009.
   PubMed Web of Science ®Google Scholar
• Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, Sun J, Yang Q, Zhang X, Lu B. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One. 2012;7(2):e30676. doi:10.1371/journal.pone.0030676. Epub 2012/03/01. PubMed PMID: 22363469; PubMed Central PMCID: PMC3281852.
   PubMed Web of Science ®Google Scholar
• Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010;207(10):2175–2186. doi:10.1084/jem.20100637. Epub 2010/ 09/08. PubMed PMID: 20819923; PubMed Central PMCID: PMC2947081.
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010; 207(10):2187–2194. doi:10.1084/jem.20100643. Epub 2010/09/08. PubMed PMID: 20819927; PubMed Central PMCID: PMC2947065.
   PubMed Web of Science ®Google Scholar
• Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DAA, Wherry EJ. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10(1):29–37. doi:10.1038/ni.1679. Epub 2008/ 12/02. PubMed PMID: 19043418; PubMed Central PMCID: PMCPMC2605166.
   PubMed Web of Science ®Google Scholar
• Chihara N, Madi A, Kondo T, Zhang H, Acharya N, Singer M, Nyman J, Marjanovic ND, Kowalczyk MS, Wang C, et al. Induction and transcriptional regulation of the co-inhibitory gene module in T cells. Nature. 2018;558(7710):454–459. doi:10.1038/s41586-018-0206-z. Epub 2018/06/15. PubMed PMID: 29899446; PubMed Central PMCID: PMCPMC6130914.
   PubMed Web of Science ®Google Scholar
• Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, Ferris RL, Delgoffe GM. The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. Immunity. 2016;45(2):374–388. doi:10.1016/j.immuni.2016.07.009. Epub 2016/08/09. PubMed PMID: 27496732; PubMed Central PMCID: PMCPMC5207350.
   PubMed Web of Science ®Google Scholar
• Vilgelm AE, Johnson DB, Richmond A. Combinatorial approach to cancer immunotherapy: strength in numbers. J Leukoc Biol. 2016; 100(2):275–290. doi:10.1189/jlb.5RI0116-013RR. Epub 2016/ 06/04. PubMed PMID: 27256570.
   PubMed Web of Science ®Google Scholar
• Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010;107(17):7875–7880. doi:10.1073/pnas.1003345107. Epub 2010/ 04/14. PubMed PMID: 20385810; PubMed Central PMCID: PMCPMC2867907.
   PubMed Web of Science ®Google Scholar
• Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72(4):917–927. doi:10.1158/0008-5472.CAN-11-1620. Epub 2011/ 12/22. PubMed PMID: 22186141; PubMed Central PMCID: PMCPMC3288154.
   PubMed Web of Science ®Google Scholar
• Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum M, Daud A, Barber DL, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014;26(5):638–652. doi:10.1016/j.ccell.2014.09.007. Epub 2014/12/03. PubMed PMID: 25446897; PubMed Central PMCID: PMCPMC4254577.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690. Epub 2012/06/05. PubMed PMID: 22658127; PubMed Central PMCID: PMC3544539.
   PubMed Web of Science ®Google Scholar
• Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011; 71(10):3540–3551. doi:10.1158/0008-5472.CAN-11-0096. Epub 2011/03/25. PubMed PMID: 21430066.
   PubMed Web of Science ®Google Scholar
• Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501. doi:10.1038/ncomms10501. PubMed PMID: 26883990; PubMed Central PMCID: PMC4757784.
   PubMed Web of Science ®Google Scholar
• Kato R, Yamasaki M, Urakawa S, Nishida K, Makino T, Morimoto-Okazawa A, Kawashima A, Iwahori K, Suzuki S, Ueda R, et al. Increased Tim-3+ T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients. Cancer Immunol Immunother. 2018;67(11):1673–1683. doi:10.1007/s00262-018-2225-x. Epub 2018/ 08/22. PubMed PMID: 30128737.
   PubMed Web of Science ®Google Scholar
• Shi L, Chen L, Wu C, Zhu Y, Xu B, Zheng X, Sun M, Wen W, Dai X, Yang M, et al. PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. Clin Cancer Res. 2016;22(5):1173–1184. doi:10.1158/1078-0432.CCR-15-1352. PubMed PMID: 26933175; PubMed Central PMCID: PMC4780056.
   PubMed Web of Science ®Google Scholar
• Li J, Shayan G, Avery L, Jie HB, Gildener-Leapman N, Schmitt N, Lu BF, Kane LP, Ferris RL. Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: evidence for intracellular cross talk. Oncoimmunology. 2016;5(10):e1200778. doi:10.1080/2162402X.2016.1200778. Epub 2016/ 11/18. PubMed PMID: 27853635; PubMed Central PMCID: PMCPMC5087305.
   PubMed Web of Science ®Google Scholar
• Granier C, Dariane C, Combe P, Verkarre V, Urien S, Badoual C, Roussel H, Mandavit M, Ravel P, Sibony M, et al. Tim-3 Expression on Tumor-Infiltrating PD-1(+)CD8(+) T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma. Cancer Res. 2017;77(5):1075–1082. doi:10.1158/0008-5472.CAN-16-0274. Epub 2016/ 11/23. PubMed PMID: 27872087.
   PubMed Web of Science ®Google Scholar
• Mohme M, Schliffke S, Maire CL, Runger A, Glau L, Mende KC, Matschke J, Gehbauer C, Akyüz N, Zapf S, et al. Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes. Clin Cancer Res. 2018;24(17):4187–4200. doi:10.1158/1078-0432.CCR-17-2617. Epub 2018/02/16. PubMed PMID: 29444930.
   PubMed Web of Science ®Google Scholar
• Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, Chandwaskar R, Karman J, Su EW, Hirashima M, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 2007;318(5853):1141–1143. doi:10.1126/science.1148536. PubMed PMID: 18006747.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ma CJ, Wang JM, Ji XJ, Wu XY, Moorman JP, Yao ZQ. Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytes. J Leukoc Biol. 2012;91(2):189–196. doi:10.1189/jlb.1010591. Epub 2011/ 08/17. PubMed PMID: 21844165; PubMed Central PMCID: PMCPMC3290426.
   PubMed Web of Science ®Google Scholar
• de Mingo Pulido A, Gardner A, Hiebler S, Soliman H, Rugo HS, Krummel MF, Coussens LM, Ruffell B. TIM-3 Regulates CD103(+) Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell. 2018;33(1):60–74 e6. doi:10.1016/j.ccell.2017.11.019. Epub 2018/01/10. PubMed PMID: 29316433; PubMed Central PMCID: PMCPMC5764109.
   PubMed Web of Science ®Google Scholar
• Ocana-Guzman R, Torre-Bouscoulet L, Sada-Ovalle I. TIM-3 Regulates Distinct Functions in Macrophages. Front Immunol. 2016;7:229. doi:10.3389/fimmu.2016.00229. Epub 2016/07/06. PubMed PMID: 27379093; PubMed Central PMCID: PMCPMC4904032.
   PubMed Web of Science ®Google Scholar
• Ma CJ, Ren JP, Li GY, Wu XY, Brockstedt DG, Lauer P, Moorman JP, Yao ZQ. Enhanced virus-specific CD8+ T cell responses by Listeria monocytogenes-infected dendritic cells in the context of Tim-3 blockade. PLoS One. 2014;9(1):e87821. doi:10.1371/journal.pone.0087821. Epub 2014/ 02/06. PubMed PMID: 24498204; PubMed Central PMCID: PMCPMC3909257.
   PubMed Web of Science ®Google Scholar
• Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, Fujioka Y, Ohba Y, Gorman JV, Colgan JD, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012;13(9):832–842. doi:10.1038/ni.2376. Epub 2012/07/31. PubMed PMID: 22842346; PubMed Central PMCID: PMCPMC3622453.
   PubMed Web of Science ®Google Scholar
• Nagahara K, Arikawa T, Oomizu S, Kontani K, Nobumoto A, Tateno H, Watanabe K, Niki T, Katoh S, Miyake M, et al. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol. 2008;181(11):7660–7669. doi:10.4049/jimmunol.181.11.7660. Epub 2008/ 11/20.PubMed PMID: 19017954; PubMed Central PMCID: PMCPMC5886706.
   PubMed Web of Science ®Google Scholar
• Moller-Hackbarth K, Dewitz C, Schweigert O, Trad A, Garbers C, Rose-John S, Scheller J. A disintegrin and metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T cell immunoglobulin and mucin domain 3 (Tim-3). J Biol Chem. 2013;288(48):34529–34544. doi:10.1074/jbc.M113.488478. Epub 2013/ 10/15. PubMed PMID: 24121505; PubMed Central PMCID: PMCPMC3843067.
   PubMed Web of Science ®Google Scholar
• Liu Z, McMichael EL, Shayan G, Li J, Chen K, Srivastava R, Kane LP, Lu B, Ferris RL. Novel Effector Phenotype of Tim-3(+) Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. Clin Cancer Res. 2018;24(18):4529–4538. doi:10.1158/1078-0432.CCR-17-1350. Epub 2018/ 05/02. PubMed PMID: 29712685; PubMed Central PMCID: PMCPMC6139056.
   PubMed Web of Science ®Google Scholar